Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

HMS faculty, help us improve the algorithms in Profiles by uploading your CV!

Steven P. Treon, M.D., Ph.D.

Co-Author

This page shows the publications co-authored by Steven Treon and Jorge Castillo.
Connection Strength

46.913
  1. Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy. Blood Adv. 2022 02 08; 6(3):1015-1024.
    View in: PubMed
    Score: 0.957
  2. Venetoclax in Previously Treated Waldenström Macroglobulinemia. J Clin Oncol. 2022 01 01; 40(1):63-71.
    View in: PubMed
    Score: 0.942
  3. Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia. Blood. 2021 10 28; 138(17):1535-1539.
    View in: PubMed
    Score: 0.939
  4. Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia. Leukemia. 2022 02; 36(2):532-539.
    View in: PubMed
    Score: 0.931
  5. Plasmablastic lymphoma transformation in a patient with Waldenström macroglobulinemia treated with ibrutinib. Br J Haematol. 2021 11; 195(3):466-468.
    View in: PubMed
    Score: 0.924
  6. Management of Waldenström macroglobulinemia in 2020. Hematology Am Soc Hematol Educ Program. 2020 12 04; 2020(1):372-379.
    View in: PubMed
    Score: 0.882
  7. Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinib. Br J Haematol. 2021 02; 192(3):542-550.
    View in: PubMed
    Score: 0.879
  8. Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenström macroglobulinemia. Blood Adv. 2020 10 27; 4(20):5089-5092.
    View in: PubMed
    Score: 0.876
  9. Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia. J Clin Oncol. 2021 02 20; 39(6):565-575.
    View in: PubMed
    Score: 0.869
  10. Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up. Blood Adv. 2020 08 25; 4(16):3952-3959.
    View in: PubMed
    Score: 0.865
  11. Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With Waldenström Macroglobulinemia on and off Clinical Trials. Hemasphere. 2020 Jun; 4(3):e363.
    View in: PubMed
    Score: 0.850
  12. Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies. J Clin Oncol. 2020 04 10; 38(11):1198-1208.
    View in: PubMed
    Score: 0.835
  13. A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and Waldenström macroglobulinemia. Leuk Lymphoma. 2020 06; 61(6):1388-1394.
    View in: PubMed
    Score: 0.832
  14. CXCR4 mutational status does not impact outcomes in patients with Waldenström macroglobulinemia treated with proteasome inhibitors. Am J Hematol. 2020 04; 95(4):E95-E98.
    View in: PubMed
    Score: 0.831
  15. Deepening of response after completing rituximab-containing therapy in patients with Waldenstrom macroglobulinemia. Am J Hematol. 2020 04; 95(4):372-378.
    View in: PubMed
    Score: 0.828
  16. What is new in the treatment of Waldenstrom macroglobulinemia? Leukemia. 2019 11; 33(11):2555-2562.
    View in: PubMed
    Score: 0.814
  17. How we manage Bing-Neel syndrome. Br J Haematol. 2019 11; 187(3):277-285.
    View in: PubMed
    Score: 0.806
  18. CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review. Expert Rev Hematol. 2019 10; 12(10):873-881.
    View in: PubMed
    Score: 0.803
  19. CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib. Br J Haematol. 2019 11; 187(3):356-363.
    View in: PubMed
    Score: 0.799
  20. Genomic landscape of Waldenström's macroglobulinemia. Hemasphere. 2019 Jun; 3(Suppl).
    View in: PubMed
    Score: 0.799
  21. Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. Blood. 2019 01 24; 133(4):299-305.
    View in: PubMed
    Score: 0.768
  22. Waldenström Macroglobulinemia: Lessons Learned from Basic and Clinical Research. Hematol Oncol Clin North Am. 2018 10; 32(5):xiii-xiv.
    View in: PubMed
    Score: 0.758
  23. Genomic Landscape of Waldenström Macroglobulinemia. Hematol Oncol Clin North Am. 2018 10; 32(5):745-752.
    View in: PubMed
    Score: 0.749
  24. Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia. J Clin Oncol. 2018 09 20; 36(27):2755-2761.
    View in: PubMed
    Score: 0.749
  25. Initial Evaluation of the Patient with Waldenström Macroglobulinemia. Hematol Oncol Clin North Am. 2018 10; 32(5):811-820.
    View in: PubMed
    Score: 0.748
  26. The real world of Waldenström's macroglobulinaemia. Lancet Haematol. 2018 07; 5(7):e275-e276.
    View in: PubMed
    Score: 0.745
  27. Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenström macroglobulinemia. Haematologica. 2018 10; 103(10):e466-e468.
    View in: PubMed
    Score: 0.739
  28. Spotting the elusive Siberian tiger: Complete response to ibrutinib in a patient with Waldenström Macroglobulinemia. Am J Hematol. 2018 May 14.
    View in: PubMed
    Score: 0.739
  29. Fitting mSMART Into the Current Clinical Management of Waldenström Macroglobulinemia. JAMA Oncol. 2018 05 01; 4(5):744-745.
    View in: PubMed
    Score: 0.737
  30. Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenström Macroglobulinemia. Clin Cancer Res. 2018 07 15; 24(14):3247-3252.
    View in: PubMed
    Score: 0.735
  31. Low levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with Waldenström macroglobulinaemia. Br J Haematol. 2019 03; 184(6):1011-1014.
    View in: PubMed
    Score: 0.730
  32. Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia. Br J Haematol. 2018 04; 181(1):77-85.
    View in: PubMed
    Score: 0.727
  33. Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemia. Haematologica. 2018 07; 103(7):e307-e310.
    View in: PubMed
    Score: 0.727
  34. Comparing apples to oranges: A commentary on the Mayo study of MYD88 significance in Waldenstrom's macroglobulinemia. Am J Hematol. 2018 03; 93(3):E69-E71.
    View in: PubMed
    Score: 0.719
  35. Toward personalized treatment in Waldenström macroglobulinemia. Hematology Am Soc Hematol Educ Program. 2017 12 08; 2017(1):365-370.
    View in: PubMed
    Score: 0.717
  36. What should be the goal of therapy for Waldenström macroglobulinemia patients? Complete response should be the goal of therapy. Blood Adv. 2017 Nov 28; 1(25):2486-2490.
    View in: PubMed
    Score: 0.716
  37. MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival. Br J Haematol. 2018 02; 180(3):374-380.
    View in: PubMed
    Score: 0.715
  38. Novel approaches to targeting MYD88 in Waldenström macroglobulinemia. Expert Rev Hematol. 2017 08; 10(8):739-744.
    View in: PubMed
    Score: 0.695
  39. Future therapeutic options for patients with Waldenström macroglobulinemia. Best Pract Res Clin Haematol. 2016 06; 29(2):206-215.
    View in: PubMed
    Score: 0.658
  40. Idelalisib in Waldenström macroglobulinemia: high incidence of hepatotoxicity. Leuk Lymphoma. 2017 04; 58(4):1002-1004.
    View in: PubMed
    Score: 0.656
  41. Histological transformation to diffuse large B-cell lymphoma in patients with Waldenström macroglobulinemia. Am J Hematol. 2016 10; 91(10):1032-5.
    View in: PubMed
    Score: 0.652
  42. Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience. Ther Adv Hematol. 2016 Aug; 7(4):179-86.
    View in: PubMed
    Score: 0.647
  43. Response to ibrutinib in a patient with IgG lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation. Leuk Lymphoma. 2016 11; 57(11):2699-701.
    View in: PubMed
    Score: 0.636
  44. Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study. Br J Haematol. 2016 Mar; 172(5):709-15.
    View in: PubMed
    Score: 0.626
  45. Rituximab intolerance in patients with Waldenström macroglobulinaemia. Br J Haematol. 2016 08; 174(4):645-8.
    View in: PubMed
    Score: 0.620
  46. Survival outcomes of secondary cancers in patients with Waldenström macroglobulinemia: An analysis of the SEER database. Am J Hematol. 2015 Aug; 90(8):696-701.
    View in: PubMed
    Score: 0.601
  47. Incidence of secondary malignancies among patients with Waldenström macroglobulinemia: An analysis of the SEER database. Cancer. 2015 Jul 01; 121(13):2230-6.
    View in: PubMed
    Score: 0.593
  48. Biology, prognosis, and therapy of Waldenström Macroglobulinemia. Cancer Treat Res. 2015; 165:177-95.
    View in: PubMed
    Score: 0.585
  49. Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database. Br J Haematol. 2015 Apr; 169(1):81-9.
    View in: PubMed
    Score: 0.583
  50. Survival trends in Waldenström macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database. Blood. 2014 Jun 19; 123(25):3999-4000.
    View in: PubMed
    Score: 0.564
  51. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia. Blood. 2014 Jul 24; 124(4):503-10.
    View in: PubMed
    Score: 0.561
  52. Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy. Haematologica. 2022 05 01; 107(5):1163-1171.
    View in: PubMed
    Score: 0.243
  53. Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia. Expert Rev Anticancer Ther. 2022 05; 22(5):471-478.
    View in: PubMed
    Score: 0.243
  54. SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenström Macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2022 08; 22(8):547-556.
    View in: PubMed
    Score: 0.240
  55. The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance. Blood. 2021 11 18; 138(20):1966-1979.
    View in: PubMed
    Score: 0.236
  56. A prognostic index predicting survival in transformed Waldenström macroglobulinemia. Haematologica. 2021 11 01; 106(11):2940-2946.
    View in: PubMed
    Score: 0.235
  57. How to Sequence Therapies in Waldenström Macroglobulinemia. Curr Treat Options Oncol. 2021 08 23; 22(10):92.
    View in: PubMed
    Score: 0.232
  58. Bone marrow involvement and subclonal diversity impairs detection of mutated CXCR4 by diagnostic next-generation sequencing in Waldenström macroglobulinaemia. Br J Haematol. 2021 08; 194(4):730-733.
    View in: PubMed
    Score: 0.225
  59. Reducing treatment toxicity in Waldenström macroglobulinemia. Expert Opin Drug Saf. 2021 Jun; 20(6):669-676.
    View in: PubMed
    Score: 0.224
  60. Clinical application of genomics in Waldenström macroglobulinemia. Leuk Lymphoma. 2021 08; 62(8):1805-1815.
    View in: PubMed
    Score: 0.223
  61. Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. Lancet Haematol. 2020 Nov; 7(11):e827-e837.
    View in: PubMed
    Score: 0.219
  62. Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic. Hemasphere. 2020 Aug; 4(4):e433.
    View in: PubMed
    Score: 0.215
  63. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Blood. 2020 05 21; 135(21):1912-1915.
    View in: PubMed
    Score: 0.212
  64. CXCR4S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia. Blood Adv. 2019 10 08; 3(19):2800-2803.
    View in: PubMed
    Score: 0.203
  65. Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia. Blood Adv. 2018 11 13; 2(21):2937-2946.
    View in: PubMed
    Score: 0.191
  66. Long survival in patients with Waldenström macroglobulinaemia diagnosed at a young age. Br J Haematol. 2019 05; 185(4):799-802.
    View in: PubMed
    Score: 0.191
  67. Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM rebound. Am J Hematol. 2018 08; 93(4):511-517.
    View in: PubMed
    Score: 0.181
  68. Comparative outcomes of immunochemotherapy regimens in Waldenström macroglobulinaemia. Br J Haematol. 2017 10; 179(1):106-115.
    View in: PubMed
    Score: 0.174
  69. Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenström macroglobulinaemia. Br J Haematol. 2017 06; 177(5):717-725.
    View in: PubMed
    Score: 0.172
  70. Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia. Blood. 2017 05 04; 129(18):2519-2525.
    View in: PubMed
    Score: 0.170
  71. Genomics, Signaling, and Treatment of Waldenström Macroglobulinemia. J Clin Oncol. 2017 Mar 20; 35(9):994-1001.
    View in: PubMed
    Score: 0.169
  72. Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214). Clin Cancer Res. 2017 May 15; 23(10):2400-2404.
    View in: PubMed
    Score: 0.166
  73. MYD88 mutations can be used to identify malignant pleural effusions in Waldenström macroglobulinaemia. Br J Haematol. 2018 02; 180(4):578-581.
    View in: PubMed
    Score: 0.166
  74. Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome. Haematologica. 2017 01; 102(1):43-51.
    View in: PubMed
    Score: 0.165
  75. Renal disease related to Waldenström macroglobulinaemia: incidence, pathology and clinical outcomes. Br J Haematol. 2016 Nov; 175(4):623-630.
    View in: PubMed
    Score: 0.163
  76. Evolution of Management and Outcomes in Waldenström Macroglobulinemia: A Population-Based Analysis. Oncologist. 2016 Nov; 21(11):1377-1386.
    View in: PubMed
    Score: 0.163
  77. Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia. Br J Haematol. 2016 10; 175(1):77-86.
    View in: PubMed
    Score: 0.162
  78. Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia. Blood. 2016 08 11; 128(6):827-38.
    View in: PubMed
    Score: 0.162
  79. HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib. Blood. 2016 06 23; 127(25):3237-52.
    View in: PubMed
    Score: 0.160
  80. Atrial fibrillation associated with ibrutinib in Waldenström macroglobulinemia. Am J Hematol. 2016 06; 91(6):E312-3.
    View in: PubMed
    Score: 0.160
  81. To select or not to select? The role of B-cell selection in determining the MYD88 mutation status in Waldenström Macroglobulinaemia. Br J Haematol. 2017 03; 176(5):822-824.
    View in: PubMed
    Score: 0.159
  82. Inhibition of the Bruton Tyrosine Kinase Pathway in B-Cell Lymphoproliferative Disorders. Cancer J. 2016 Jan-Feb; 22(1):34-9.
    View in: PubMed
    Score: 0.157
  83. Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia. Br J Haematol. 2016 Mar; 172(5):735-44.
    View in: PubMed
    Score: 0.156
  84. Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia. Leukemia. 2015 Dec; 29(12):2338-46.
    View in: PubMed
    Score: 0.151
  85. Ibrutinib in previously treated Waldenström's macroglobulinemia. N Engl J Med. 2015 Apr 09; 372(15):1430-40.
    View in: PubMed
    Score: 0.149
  86. The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells. Br J Haematol. 2015 Jul; 170(1):134-8.
    View in: PubMed
    Score: 0.147
  87. CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenström macroglobulinaemia cells. Br J Haematol. 2015 Mar; 168(5):701-7.
    View in: PubMed
    Score: 0.145
  88. Waldenström macroglobulinemia. Hematol Oncol Clin North Am. 2014 Oct; 28(5):945-70.
    View in: PubMed
    Score: 0.142
  89. The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia. Leukemia. 2015 Jan; 29(1):169-76.
    View in: PubMed
    Score: 0.141
  90. Detection of MYD88 L265P in peripheral blood of patients with Waldenström's Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. Leukemia. 2014 Aug; 28(8):1698-704.
    View in: PubMed
    Score: 0.137
  91. High frequency of central nervous system involvement in transformed Waldenström macroglobulinemia. Blood Adv. 2022 06 28; 6(12):3655-3658.
    View in: PubMed
    Score: 0.061
  92. A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas. Blood Adv. 2022 06 14; 6(11):3332-3338.
    View in: PubMed
    Score: 0.061
  93. Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenström macroglobulinemia. Blood Adv. 2022 04 12; 6(7):2230-2235.
    View in: PubMed
    Score: 0.061
  94. Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome. Blood. 2021 11 18; 138(20):2002-2005.
    View in: PubMed
    Score: 0.059
  95. Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88L265P in Waldenström Macroglobulinemia. Hemasphere. 2021 Aug; 5(8):e624.
    View in: PubMed
    Score: 0.058
  96. Cell-free DNA analysis for detection of MYD88L265P and CXCR4S338X mutations in Waldenström macroglobulinemia. Am J Hematol. 2021 07 01; 96(7):E250-E253.
    View in: PubMed
    Score: 0.057
  97. Comparative genomics of CXCR4MUT and CXCR4WT single cells in Waldenström's macroglobulinemia. Blood Adv. 2020 09 22; 4(18):4550-4553.
    View in: PubMed
    Score: 0.054
  98. Genomic evolution of ibrutinib-resistant clones in Waldenström macroglobulinaemia. Br J Haematol. 2020 06; 189(6):1165-1170.
    View in: PubMed
    Score: 0.052
  99. SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas. Blood Cancer J. 2020 01 31; 10(1):12.
    View in: PubMed
    Score: 0.052
  100. Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomas. Blood Adv. 2020 01 14; 4(1):141-153.
    View in: PubMed
    Score: 0.052
  101. Reply to F.D. Leonard. J Clin Oncol. 2019 10 10; 37(29):2701-2702.
    View in: PubMed
    Score: 0.050
  102. Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia. J Clin Oncol. 2019 06 01; 37(16):1403-1411.
    View in: PubMed
    Score: 0.049
  103. Low risk of Pneumocystis jirovecii pneumonia and invasive aspergillosis in patients with Waldenström macroglobulinaemia on ibrutinib. Br J Haematol. 2019 05; 185(4):788-790.
    View in: PubMed
    Score: 0.048
  104. Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients. Blood. 2018 12 13; 132(24):2608-2612.
    View in: PubMed
    Score: 0.048
  105. Profiling of circulating exosomal miRNAs in patients with Waldenström Macroglobulinemia. PLoS One. 2018; 13(10):e0204589.
    View in: PubMed
    Score: 0.047
  106. TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemia. Br J Haematol. 2019 01; 184(2):242-245.
    View in: PubMed
    Score: 0.047
  107. MYD88 mutated and wild-type Waldenström's Macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in CXCR4. Haematologica. 2018 09; 103(9):e408-e411.
    View in: PubMed
    Score: 0.046
  108. BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism. Blood. 2018 05 03; 131(18):2047-2059.
    View in: PubMed
    Score: 0.046
  109. CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinib. Haematologica. 2017 11; 102(11):e452-e455.
    View in: PubMed
    Score: 0.044
  110. Investigation and management of IgM and Waldenström-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel. Br J Haematol. 2017 03; 176(5):728-742.
    View in: PubMed
    Score: 0.042
  111. Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol. 2017 Feb; 18(2):241-250.
    View in: PubMed
    Score: 0.042
  112. Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. Blood. 2016 09 08; 128(10):1321-8.
    View in: PubMed
    Score: 0.041
  113. Ibrutinib penetrates the blood brain barrier and shows efficacy in the therapy of Bing Neel syndrome. Br J Haematol. 2017 10; 179(2):339-341.
    View in: PubMed
    Score: 0.041
  114. Targeting Myddosome Assembly in Waldenstrom Macroglobulinaemia. Br J Haematol. 2017 06; 177(5):808-813.
    View in: PubMed
    Score: 0.040
  115. Exome sequencing reveals recurrent germ line variants in patients with familial Waldenström macroglobulinemia. Blood. 2016 05 26; 127(21):2598-606.
    View in: PubMed
    Score: 0.040
  116. Cyclophosphamide, bortezomib, and dexamethasone combination in waldenstrom macroglobulinemia. Am J Hematol. 2015 Jun; 90(6):E122-3.
    View in: PubMed
    Score: 0.037
  117. Extramedullary Waldenström macroglobulinemia. Am J Hematol. 2015 Feb; 90(2):100-4.
    View in: PubMed
    Score: 0.036
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.